Polianta Ltd Has $1.31 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Polianta Ltd grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,000 shares of the medical research company’s stock after acquiring an additional 700 shares during the quarter. Bio-Rad Laboratories accounts for 0.6% of Polianta Ltd’s holdings, making the stock its 26th biggest position. Polianta Ltd’s holdings in Bio-Rad Laboratories were worth $1,314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $32,000. Point72 Hong Kong Ltd bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at approximately $55,000. Quarry LP acquired a new position in Bio-Rad Laboratories during the 2nd quarter worth approximately $59,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Bio-Rad Laboratories by 281.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company’s stock worth $91,000 after acquiring an additional 200 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Down 0.4 %

Bio-Rad Laboratories stock opened at $342.95 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The company’s 50-day moving average is $336.49 and its 200-day moving average is $330.25.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. During the same period in the prior year, the firm earned $2.33 EPS. The business’s revenue was up 2.8% on a year-over-year basis. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BIO shares. Citigroup boosted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada restated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.